Currently out of the existing stock ratings of Brian Cheng, 36 are a BUY (76.6%), 10 are a HOLD (21.28%), 1 are a SELL (2.13%).

Brian Cheng

Work Performance Price Targets & Ratings Chart

Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 38.1% that have a potential upside of 17.58% achieved within 53 days.

Brian Cheng’s has documented 93 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 12-Aug-2024.

Wall Street Analyst Brian Cheng

Analyst best performing recommendations are on APLS (APELLIS PHARMACEUTICALS).
The best stock recommendation documented was for APLS (APELLIS PHARMACEUTICALS) at 10/12/2023. The price target of $46 was fulfilled within 1 day with a profit of $2.1 (4.78%) receiving and performance score of 47.84.

Average potential price target upside

of $12.41 (54.76%) on SRRA (SIERRA ONCOLOGY).
of $9.94 (44.95%) on PTGX (PROTAGONIST THERAPEUTICS).
of $8.96 (27.57%) on APLS (APELLIS PHARMACEUTICALS).

ARCT Arcturus Therapeutics Holdings PSTX Poseida Therapeutics ADCT ADC Therapeutics SA IMNM Immunome SRRA Sierra Oncology GOSS Gossamer Bio APLS Apellis Pharmaceuticals NTLA Intellia Therapeutics ROIV Roivant Sciences Ltd XNCR Xencor ACET Adicet Bio BCAB Bioatla ALLO Allogene Therapeutics MRSN Mersana Therapeutics PTGX Protagonist Therapeutics ZYME Zymeworks . Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ed Arce (HC WAINWRIGHT)